IGC Pharma (IGC) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology firm focused on developing AI-driven therapies for Alzheimer's and metabolic disorders.

• Lead drug candidate, IGC-AD1, is in Phase 2 clinical trials targeting agitation in Alzheimer's patients, with interim data showing statistically significant reduction in agitation and sleep disturbances.

• Pipeline includes multiple small-molecule assets targeting various Alzheimer's disease mechanisms and an AI tool (MINT-AD) for early detection and clinical trial optimization.

• Long-term strategy aims to build a portfolio of differentiated therapies addressing both symptoms and disease modification.

Financial performance and metrics

• Recent share purchase agreements resulted in the sale of 2,803,333 shares for $841,000 at $0.30 per share, subject to NYSE approval and customary closing conditions.

• As of June 20, 2025, 83,891,586 shares of common stock were outstanding, with additional shares reserved for awards, options, and grants.

Use of proceeds and capital allocation

• No proceeds will be received by the company from this offering; all shares are being sold by existing stockholders.

• Company will bear all registration-related costs, but not brokerage or selling expenses incurred by stockholders.